EP4732016A1 - Verfahren zur diagnose von lebersteatose - Google Patents

Verfahren zur diagnose von lebersteatose

Info

Publication number
EP4732016A1
EP4732016A1 EP24735976.3A EP24735976A EP4732016A1 EP 4732016 A1 EP4732016 A1 EP 4732016A1 EP 24735976 A EP24735976 A EP 24735976A EP 4732016 A1 EP4732016 A1 EP 4732016A1
Authority
EP
European Patent Office
Prior art keywords
patient
steatosis
patients
subject
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24735976.3A
Other languages
English (en)
French (fr)
Inventor
Thierry Poynard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopredictive
Original Assignee
Biopredictive
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP23305987.2A external-priority patent/EP4481388A1/de
Priority claimed from EP23305989.8A external-priority patent/EP4481390A1/de
Priority claimed from EP23305988.0A external-priority patent/EP4481389A1/de
Application filed by Biopredictive filed Critical Biopredictive
Publication of EP4732016A1 publication Critical patent/EP4732016A1/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/728—Bilirubin; including biliverdin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/02—Triacylglycerols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP24735976.3A 2023-06-21 2024-06-20 Verfahren zur diagnose von lebersteatose Pending EP4732016A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23305987.2A EP4481388A1 (de) 2023-06-21 2023-06-21 Verfahren zur diagnose von lebersteatose
EP23305989.8A EP4481390A1 (de) 2023-06-21 2023-06-21 Verfahren zur diagnose von leberfibrose
EP23305988.0A EP4481389A1 (de) 2023-06-21 2023-06-21 Verfahren zur diagnose von nichtalkoholischer steatotischer hepatitis
PCT/EP2024/067358 WO2024261197A1 (en) 2023-06-21 2024-06-20 Method of diagnosis of liver steatosis

Publications (1)

Publication Number Publication Date
EP4732016A1 true EP4732016A1 (de) 2026-04-29

Family

ID=91663885

Family Applications (3)

Application Number Title Priority Date Filing Date
EP24735977.1A Pending EP4732017A1 (de) 2023-06-21 2024-06-20 Verfahren zur diagnose von nichtalkoholischer steatotischer hepatitis
EP24735976.3A Pending EP4732016A1 (de) 2023-06-21 2024-06-20 Verfahren zur diagnose von lebersteatose
EP24735630.6A Pending EP4732015A1 (de) 2023-06-21 2024-06-20 Verfahren zur diagnose von leberfibrose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24735977.1A Pending EP4732017A1 (de) 2023-06-21 2024-06-20 Verfahren zur diagnose von nichtalkoholischer steatotischer hepatitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24735630.6A Pending EP4732015A1 (de) 2023-06-21 2024-06-20 Verfahren zur diagnose von leberfibrose

Country Status (2)

Country Link
EP (3) EP4732017A1 (de)
WO (3) WO2024261197A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420089C (en) 2000-08-21 2009-04-14 Assistance Publique-Hopitaux De Paris Diagnosis method of fibrotic disease using biochemical markers
WO2014049131A1 (en) 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
EP3296744A1 (de) 2016-09-16 2018-03-21 Biopredictive Verfahren zur diagnose nichtalkoholischer fettlebererkrankungen
EP3599615A1 (de) 2018-07-27 2020-01-29 Biopredictive Verfahren zur diagnose von lebersteatose

Also Published As

Publication number Publication date
EP4732017A1 (de) 2026-04-29
WO2024261199A1 (en) 2024-12-26
EP4732015A1 (de) 2026-04-29
WO2024261197A1 (en) 2024-12-26
WO2024261198A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
Long et al. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review
Bril et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes
CN112805789B (zh) 诊断肝脂肪变性的方法
US20250306025A1 (en) Method of prognosis and follow up of primary liver cancer
Hsu et al. Body mass index and risk for end-stage renal disease
Vatsalya et al. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis
Chung et al. Time to glucose peak during an oral glucose tolerance test identifies prediabetes risk
Dowman et al. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
Bril et al. Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus
EP3513193B1 (de) Verfahren zur diagnose nichtalkoholischer fettlebererkrankungen
Van Son et al. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies
Harrison et al. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
Wan et al. Applicability and results of liver stiffness measurement and controlled attenuation parameter using XL probe for metabolic-associated fatty liver disease in candidates to bariatric surgery. A single-center observational study
Ko et al. Chronic pancreatitis is characterized by elevated circulating periostin levels related to intra-pancreatic fat deposition
Alfadda et al. Predictors of liver fibrosis progression in cohort of type 2 diabetes mellitus patients with MASLD
Gabriel-Medina et al. Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level
Marti‐Aguado et al. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score
Lee et al. The prevalence of advanced liver fibrosis among patients with type 2 diabetes mellitus: a single-centre experience in penang, malaysia
Cho et al. Synergistic effect of non-alcoholic fatty liver disease and history of gestational diabetes to increase risk of type 2 diabetes
EP4481388A1 (de) Verfahren zur diagnose von lebersteatose
EP4481389A1 (de) Verfahren zur diagnose von nichtalkoholischer steatotischer hepatitis
EP4481390A1 (de) Verfahren zur diagnose von leberfibrose
Azarboo et al. The association between cardiometabolic index (CMI) and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
EP4732016A1 (de) Verfahren zur diagnose von lebersteatose
Siwan et al. Circulating soluble CD163 as a potential biomarker of diabetes complications

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR